title: Amyloid positron emission tomography with (18)F-flutemetamol and structural magnetic resonance imaging in the classification of mild cognitive impairment and Alzheimer's disease.
abstract: OBJECTIVE
  To evaluate the contributions of amyloid-positive (Am+) and medial temporal atrophy-positive (MTA+) scans to the diagnostic classification of prodromal and probable Alzheimer's disease (AD).
  
  
  METHODS
  (18)F-flutemetamol-labeled amyloid positron emission tomography (PET) and magnetic resonance imaging (MRI) were used to classify 10 young normal, 15 elderly normal, 20 amnestic mild cognitive impairment (aMCI), and 27 AD subjects. MTA+ status was determined using a cut point derived from a previous study, and Am+ status was determined using a conservative and liberal cut point.
  
  
  RESULTS
  The rates of MRI scans with positive results among young normal, elderly normal, aMCI, and AD subjects were 0%, 20%, 75%, and 82%, respectively. Using conservative cut points, the rates of Am+ scans for these same groups of subjects were 0%, 7%, 50%, and 93%, respectively, with the aMCI group showing the largest discrepancy between Am+ and MTA+ scans. Among aMCI cases, 80% of Am+ subjects were also MTA+, and 70% of amyloid-negative (Am-) subjects were MTA+. The combination of amyloid PET and MTA data was additive, with an overall correct classification rate for aMCI of 86%, when a liberal cut point (standard uptake value ratio = 1.4) was used for amyloid positivity.
  
  
  CONCLUSIONS
  (18)F-flutemetamol PET and structural MRI provided additive information in the diagnostic classification of aMCI subjects, suggesting an amyloid-independent neurodegenerative component among aMCI subjects in this sample.
authors.affiliation: Wien Center for Alzheimer's Disease and Memory Disorders, Mount Sinai Medical Center, Miami Beach, FL, USA. Duara@msmc.com
authors.forename: Ranjan
authors.initials: R
authors.lastname: Duara
authors.forename: David A
authors.initials: DA
authors.lastname: Loewenstein
authors.forename: Qian
authors.initials: Q
authors.lastname: Shen
authors.forename: Warren
authors.initials: W
authors.lastname: Barker
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Potter
authors.forename: Daniel
authors.initials: D
authors.lastname: Varon
authors.forename: Kristen
authors.initials: K
authors.lastname: Heurlin
authors.forename: Rik
authors.initials: R
authors.lastname: Vandenberghe
authors.forename: Christopher
authors.initials: C
authors.lastname: Buckley
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000145:classification / Q000000981:diagnostic imaging / Q000473:pathology; D000682:Amyloid / Q000378:metabolism; D000814:Aniline Compounds; D052160:Benzothiazoles; D060825:Cognitive Dysfunction / Q000145:classification / Q000000981:diagnostic imaging / Q000473:pathology; D005260:Female; D006801:Humans; D016015:Logistic Models; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008297:Male; D008875:Middle Aged; D019579:Neocortex / Q000000981:diagnostic imaging / Q000378:metabolism / Q000473:pathology; D009483:Neuropsychological Tests; D049268:Positron-Emission Tomography / Q000379:methods*; D012720:Severity of Illness Index
chemical_list: D000682:Amyloid; D000814:Aniline Compounds; D052160:Benzothiazoles; C581552:flutemetamol